NeoGenomics, Inc.

NEO Shareholder News: Johnson Fistel Encourages NeoGenomics Shareholders with Losses to Contact the Firm Regarding Investigation

SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) — Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether NeoGenomics, Inc.

(“NeoGenomics” or “the Company”) (NASDAQ: NEO), any of its executive officers, or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focus on investors’ losses and whether they may be recovered under the federal securities laws.

What if I purchased NeoGenomics common stock? If you purchased NeoGenomics common stock and suffered significant losses on your investment, join our investigation now:

There is no cost or obligation to you.

What is Johnson Fistel investigating? On Monday, March 28, 2022, NeoGenomics Inc. Chief Executive Mark Mallon stepped down as the health-testing company revealed that first-quarter financials will miss guidance and rescinded its forecast for the full year, sending shares down more than 28% in pre-market trading on March 29, 2022.

What if I have relevant nonpublic information? Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program. Under the SEC program, whistleblowers who provide original information may, under certain circumstances, receive rewards totaling up to thirty percent of any successful recovery made by the SEC. For more information, contact Jim Baker at (619) 814-4471 or jimb@johnsonfistel.com.

About Johnson Fistel, LLP. Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in securities class action and derivative lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP

Investor Relations
Jim Baker, 619-814-4471
jimb@johnsonfistel.com